Biogen makes cautious bet on dry AMD as partner Catalyst Bio moves anti-C3 drug toward the clinic
Moving deeper into ophthalmology, Biogen has picked up a preclinical candidate for dry age-related macular degeneration.
Their partner of choice is Catalyst Bio, a biotech better known for its hemophilia efforts (not to be confused with rare neurological disease-focused Catalyst Pharma). For $15 million upfront and $340 million in milestones, Biogen will take over from the IND-enabling stage onward once Catalyst Bio completes the early research and manufacturing work — which Biogen will fund.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,200+ biopharma pros reading Endpoints daily — and it's free.